check_circleStudy Completed

Erectile Dysfunction

BAY38-9456 MD Formulation selection 2 x 20 mg ER prototypes

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

45 - 70 Years
  • -

  • -

Trial summary

Enrollment Goal
22
Trial Dates
September 2008 - December 2008
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Vardenafil ER (BAY38-9456)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Completed
Bayer HealthCareWuppertal, 42096, Germany

Trial design

Randomized study in a double-blind, 2-fold crossover, doubledummy multiple-dose design to investigate the safety, tolerability and pharmacokinetics of a 20 mg vardenafil extended release enteric-coated tablet formulation (E914) in comparison to a 20 mg vardenafil extended release anionic polymer tablet (E909) both formulations given od over 10 days in healthy male and female subjects
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A